Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Casirivimab/imdevimab  COVID-19 treatment studies for Casirivimab/i..  C19 studies: Casirivimab/i..  Casirivimab/i..   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Metformin
Bamlanivimab Molnupiravir
Bromhexine Nigella Sativa
Budesonide Nitazoxanide
Casirivimab/i.. Povidone-Iod..
Colchicine Probiotics
Conv. Plasma Proxalutamide
Curcumin Quercetin
Favipiravir Remdesivir
Fluvoxamine Sotrovimab
Hydroxychloro.. Vitamin A
Iota-carragee.. Vitamin C
Ivermectin Vitamin D
Melatonin Zinc

Other Adoption
 
00.250.50.7511.251.51.752+Regeneron (RCT)38%0.62 [0.29-1.33]recov. time92 (n)91 (n)Improvement, RR [CI]TreatmentControlRegeneron (RCT)71%0.29 [0.17-0.48]hosp./death18/1,35562/1,341Weinreich (RCT)50%0.50 [0.09-2.72]death2/2,0914/2,089Webb98%0.02 [0.00-0.27]death0/11557/5,536Tau​2 = 0.38; I​2 = 59.8%Early treatment67%0.33 [0.14-0.77]20/3,653123/9,05767% improvementHorby (RCT)6%0.94 [0.86-1.03]death944/4,8391,026/4,946Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment6%0.94 [0.86-1.03]944/4,8391,026/4,9466% improvementRegeneron (RCT)94%0.06 [0.00-1.10]symp. case0/1868/223Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP94%0.06 [0.00-1.10]0/1868/22394% improvementO'Brien (DB RCT)89%0.11 [0.01-2.06]hosp./ER0/7534/752Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP89%0.11 [0.01-2.06]0/7534/75289% improvementAll studies64%0.36 [0.16-0.78]964/9,4311,161/14,97864% improvement7 casirivimab/imdevimab COVID-19 studiesc19regn.com Oct 19, 2021Tau​2 = 0.61; I​2 = 82.5%; Z = 2.56Effect extraction pre-specifiedFavors casiri/imdevimabFavors control
Database of all casirivimab/imdevimab COVID-19 studies. Submit updates/corrections.
Jun 23
Early Webb et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab331 (Peer Reviewed) death, ↓98.3%, p=0.63 Real-World Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients with Early COVID-19
Details   Retrospective 115 patients treated with casirivimab/imdevimab showing lower mortality, hospital admission, and emergency department visits with treatment. Authors falsely state that "no other COVID-19 therapies for ambulatory patient..
Jun 16
Late Horby et al., medRxiv, doi:10.1101/2021.06.15.21258542 (Preprint) death, ↓6.0%, p=0.17 Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Details   RCT 9,785 hospitalized patients in the UK showing lower mortality with casirivimab/imdevimab, with statistical significance reached for baseline seronegative patients.
May 21
Early Weinreich et al., NEJM, doi:10.1056/NEJMoa2108163 (preprint 5/21/2021) (Peer Reviewed) death, ↓50.0%, p=0.45 REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
Details   RCT 4,057 outpatients with >=1 risk factor for severe disease, showing significantly lower combined hospitalization/death, and significantly faster recovery with treatment. Median time from onset of symptoms 3 days. NCT04425629.
Apr 12
PEP O'Brien et al., NEJM, doi:10.1056/NEJMoa2109682 (Peer Reviewed) hosp./ER, ↓88.9%, p=0.06 Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
Details   Prophylaxis trial reporting lower hospitalization/ER and symptomatic cases, and faster recovery with 1,200mg subcutaneous casirivimab with imdevimab. NCT04452318.
Mar 23
Early Regeneron Press Release (Preprint) hosp./death, ↓71.3%, p<0.0001 New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19
Details   Press release for new phase III data showing lower hospitalization/mortality, and faster symptom resolution among the subset of patients with at least one risk factor. Some variants may escape antibodies [1].
Jan 26
PrEP Regeneron Press Release (Preprint) symp. case, ↓93.6%, p=0.009 Regeneron Reports Positive Interim Data with REGEN-COV™ Antibody Cocktail used as Passive Vaccine to Prevent COVID-19
Details   Interim results of REGEN-COV prophylaxis showing 100% prevention of symptomatic infection (8/223 placebo vs. 0/186 REGEN-COV), and approximately 50% lower overall rates of infection (symptomatic and asymptomatic) (23/223 placebo vs. 10/18..
Sep 29
2020
Early Regeneron Press Release (Preprint) recov. time, ↓38.0%, p=0.22 Regeneron's REGN-COV2 antibody cocktail reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients
Details   Analysis of the first 275 patients in a trial of the REGN-COV2 antibody cocktail showing reductions in viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19. Greatest improvements were seen with patients..
Aug 21
2020
In Vitro Baum et al., Science, 21 Aug 2020, 369:6506, 1014-1018, doi:10.1126/science.abd0831 (Peer Reviewed) (In Vitro) in vitro Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
Details   In Vitro study showing that, under pressure from individual antibodies, mutant viruses were rapidly selected that evaded the blocking function of all individual antibodies tested, including antibodies that potently bind to highly-conserve..
Aug 21
2020
Animal Hansen et al., Science, 21 Aug 2020, 369:6506, 1010-1014, doi:10.1126/science.abd0827 (Peer Reviewed) animal study Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
Details   Study using humanized mice and blood samples from recovered COVID-19 patients to generate antibodies targeting multiple different regions of the critical receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. The spike protein on ..
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit